Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

```json { "title": "Intellia's CRISPR Drug Succeeds in Phase 3 Trial", "metaDescription": "Intellia Therapeutics' CRISPR gene editing therapy lonvo-z met all Phase 3 HAELO trial endpoints for hereditary angioedema — a global first in gene editing.", "content": "<h2>Intellia Therapeutics Reports Positive Phase 3 CRISPR Trial Results, Marking a Global First for In Vivo Gene Editing</h2><p>Intellia Therapeutics (Nasdaq: NTLA) announced on April 27, 2026 that its CRISPR-based therapy lonvoguran ziclumeran — known as lonvo-z — met its primary and all key secondary endpoints in the Phase 3 HAELO clinical trial for hereditary angioedema (HAE). The Cambridge, Massachusetts-based biopharmaceutical company described the readout as the world's first Phase 3 data reported for an in vivo CRISPR gene editing therapy, a milestone that carries significant implications not only for HAE patients but for the broader field of precision medicine.</p><p>HAE is a rare genetic condition estimated to affect approximately 1 in 50,000 people globally — with a pooled global prevalence of 1.22 cases per 100,000 people, according to a systematic review and meta-analysis published in the <em>International Archives of Allergy and Immunology</em>. The condition causes recurrent, unpredictable, and potentially life-threatening episodes of swelling. In the United States alone, HAE episodes result in an estimated 15,000 to 30,000 annual emergency department admissions.</p><p>Current treatments require ongoing, sometimes frequent administration — and breakthrough attacks can still occur despite chronic prophylaxis. Lonvo-z is designed to change that calculus entirely: a single intravenous infusion intended to permanently lower the levels of kallikrein and bradykinin responsible for triggering swelling attacks.</p><h2>What the Phase 3 HAELO Trial Found</h2><p>The HAELO trial is a randomized, double-blind, placebo-controlled study enrolling at least 60 adults and adolescents aged 16 and older with Type I or Type II HAE. Patients were randomized 2:1 to receive either a single 50 mg infusion of lonvo-z or a placebo. Intellia dosed the first patient in January 2025 and completed enrollment within nine months, with nearly half of enrolled patients coming from the United States.</p><p>According to Intellia's official April 27, 2026 press release, the trial met its primary and all key secondary endpoints, with favorable safety and tolerability data observed throughout the six-month efficacy evaluation period. Most notably, a single dose of lonvo-z freed most patients from both HAE attacks and the need for ongoing therapy during that period — a result the company says demonstrates its potential to be the first and only one-time treatment for HAE.</p><p>Intellia simultaneously initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration and is targeting a potential U.S. commercial launch of lonvo-z in the first half of 2027, subject to FDA approval.</p><h2>A Strong Clinical Evidence Trail Leading to Phase 3</h2><p>The Phase 3 results did not arrive without a substantial body of earlier evidence. In Phase 1 data published in the <em>New England Journal of Medicine</em> in January 2024, a single dose of the therapy — then known as NTLA-2002 — produced a 95% mean reduction in monthly HAE attack rates, with 9 of 10 patients remaining completely attack-free through the latest follow-up.</p><p>Phase 2 data, also published in the <em>New England Journal of Medicine</em>, showed that 73% of patients (8 of 11) in the 50 mg arm were completely attack-free following a one-time infusion through the latest follow-up, and that the 50 mg dose reduced kallikrein levels by 86% from baseline.</p><p>At the AAAAI 2026 conference in March 2026, Intellia presented pooled Phase 1/2 data from a cohort of 32 patients given the one-time 50 mg dose. That analysis showed a 96% mean reduction in HAE attacks versus baseline, with 31 of 32 patients — 97% — attack-free at the data cutoff.</p><p>The consistency of these results across Phase 1, Phase 2, and now Phase 3 strengthens the evidentiary foundation for lonvo-z ahead of its regulatory review.</p><h2>How Lonvo-z Works: The Science Behind the Therapy</h2><p>Lonvo-z is an in vivo CRISPR gene editing candidate built on Nobel Prize-winning CRISPR/Cas9 technology. The therapy uses Intellia's proprietary non-viral delivery platform, deploying lipid nanoparticles to carry two components to liver cells: a guide RNA specific to the kallikrein B1 (KLKB1) gene, and messenger RNA encoding the Cas9 enzyme. Together, these components inactivate the KLKB1 gene, permanently lowering kallikrein and bradykinin levels — the proteins that drive HAE swelling attacks.</p><p>The therapy is administered as a single outpatient intravenous infusion, a delivery profile that contrasts sharply with existing HAE treatments, some of which require subcutaneous injections as frequently as twice per week. Lonvo-z has received five regulatory designations across major markets: Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA; Innovation Passport from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA); Priority Medicines (PRIME) Designation from the European Medicines Agency; and Orphan Drug Designation from the European Commission.</p><h2>Why This Milestone Matters for Gene Editing and Rare Disease</h2><p>The HAELO Phase 3 readout is not just a clinical milestone for Intellia — it is a landmark moment for the field of in vivo CRISPR gene editing as a whole. Until now, CRISPR-based therapies had progressed through Phase 1 and Phase 2 studies, but no in vivo gene editing candidate had produced Phase 3 efficacy and safety data. Intellia's announcement changes that.</p><p>In vivo gene editing — where the editing machinery is delivered directly into a living patient, rather than editing cells outside the body and reinfusing them — has long been considered a more scalable and accessible modality than ex vivo approaches. A successful Phase 3 readout for lonvo-z, followed by potential FDA approval, could open the door for in vivo CRISPR therapies to pursue regulatory pathways across a wider range of diseases.</p><p>The HAE treatment landscape itself is becoming increasingly competitive. Approved options now include Takeda's Takhzyro, Ionis's Dawnzera — which received U.S. approval in 2025 — and KalVista's Ekterly, the first oral on-demand HAE treatment to receive FDA clearance. Lonvo-z would enter this market as the only one-time therapy, a differentiation that could be meaningful for patients seeking freedom from chronic treatment regimens.</p><p>Financially, Intellia reported $605.1 million in cash, cash equivalents, and marketable securities at the end of full-year 2025 — a runway the company expects will fund operations into the second half of 2027, covering the anticipated BLA review period and the early stages of a potential U.S. launch.</p><h2>Expert Reactions</h2><p>John Leonard, M.D., Intellia's President and Chief Executive Officer, framed the result in terms of both scientific history and patient impact. "As the first Phase 3 data reported for an in vivo gene editing therapy, today's HAELO results represent a profound milestone for Intellia, the broader CRISPR and precision medicine fields and, most importantly, the HAE community," Leonard said in the company's press release.</p><p>Leonard also spoke to the lived experience of HAE patients: "For those patients who have spent years battling unpredictable breakthrough swelling attacks, anxiety about their next attack or the many burdens associated with chronic prophylactic treatment, lonvo-z represents a potential paradigm shift in treatment."</p><p>Aleena Banerji, M.D., Professor at Harvard Medical School, Clinical Director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital, and HAELO principal investigator, had previously commented on earlier-stage data: "Based on results from the Phase 1/2 study, lonvo-z shows great promise to positively transform the HAE treatment paradigm."</p><h2>What Comes Next for Lonvo-z and Intellia</h2><p>With the Phase 3 HAELO trial delivering positive results and a rolling BLA submission now underway with the FDA, the immediate focus for Intellia shifts to the regulatory process. The company is preparing for a potential U.S. launch of lonvo-z in the first half of 2027, contingent on FDA approval.</p><p>A rolling BLA submission allows Intellia to submit completed sections of its application to the FDA as they become available, rather than waiting to submit everything simultaneously — a process that can shorten the overall review timeline. The RMAT Designation lonvo-z holds from the FDA also entitles Intellia to more frequent interactions with the agency during development, which may further support an efficient review process.</p><p>The full Phase 3 HAELO dataset — including detailed efficacy and safety breakdowns — has not yet been published in a peer-reviewed journal. Investors, clinicians, and regulators will be watching for that data to be presented at a medical conference or submitted for publication, which would provide a more granular picture of how lonvo-z performed across patient subgroups and over the full six-month evaluation period.</p><p>If approved, lonvo-z would become the first in vivo CRISPR gene editing therapy to reach the commercial market in the United States — a distinction that would set a significant precedent for the gene editing field and for how regulators, payers, and healthcare systems engage with one-time, potentially curative genetic medicines.</p><p>For more tech news, visit our <a href=\"/news\">news section</a>.</p><h2>The Bigger Picture for Health and Productivity</h2><p>For the millions of people managing chronic rare diseases, the prospect of a single treatment that could eliminate recurring attacks — and the anxiety, emergency visits, and ongoing medication burden that accompany them — represents more than a medical advance. It represents a potential restoration of daily function, predictability, and quality of life. That intersection of cutting-edge health technology and human productivity is exactly what platforms like Moccet exist to track. <a href=\"/#waitlist\">Join the Moccet waitlist to stay ahead of the curve.</a></p>", "excerpt": "Intellia Therapeutics announced on April 27, 2026 that its CRISPR-based therapy lonvoguran ziclumeran (lonvo-z) met all primary and key secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema — the first Phase 3 data ever reported for an in vivo CRISPR gene editing therapy. The company simultaneously initiated a rolling BLA submission to the FDA and is targeting a potential U.S. launch in the first half of 2027. A single dose freed most patients from both attacks and ongoing therapy during the six-month evaluation period.", "keywords": ["CRISPR gene editing", "Intellia Therapeutics", "hereditary angioedema", "lonvoguran ziclumeran", "Phase 3 clinical trial"], "slug": "intellia-therapeutics-crispr-phase-3-trial-hereditary-angioedema" } ```